WebOct 21, 2024 · It is an AstraZeneca-sponsored, Phase III, randomised, double-blind, placebo-controlled, multicentre trial designed to evaluate the effect of Farxiga compared with placebo on CV outcomes in adults with T2D at risk of CV events, including patients with multiple CV risk factors or established CV disease and also assessed key renal … WebJun 10, 2024 · FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58 June 10, 2024 08:00 AM Eastern ...
Farxiga (dapagliflozin) dosing, indications, …
WebIndicated to reduce risk of sustained eGFR decline, end-stage kidney disease (ESKD), cardiovascular death, and hospitalization for HF in adults with chronic kidney disease (CKD) who are at risk of progression . 10 … WebApr 11, 2024 · Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. Before ... om wraith field
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing …
WebMay 3, 2024 · In addition to priority review, Farxiga was granted Fast Track designation for this indication. Chronic kidney disease, which is defined by decreased kidney function, affects approximately 37 million people in the United States. It is typically associated with an increased risk of heart disease, stroke, or the need for dialysis or kidney ... WebMay 4, 2024 · Study findings showed that dapagliflozin reduced the primary composite measure of worsening of renal function or risk of CV or renal death by 39% compared with placebo (hazard ratio [HR] 0.61 [95% ... WebJul 15, 2024 · Effectiveness. Dapagliflozin has been shown to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes who have or are at high … omw quality measure